ID: ALA4762542

Max Phase: Preclinical

Molecular Formula: C31H32N2O7S

Molecular Weight: 576.67

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  COC(=O)c1ccc(-c2cccc([C@@H]3N(C(=O)OC(C)(C)C)CC[C@@]34C(=O)Nc3ccccc34)c2)cc1S(C)(=O)=O

Standard InChI:  InChI=1S/C31H32N2O7S/c1-30(2,3)40-29(36)33-16-15-31(23-11-6-7-12-24(23)32-28(31)35)26(33)21-10-8-9-19(17-21)20-13-14-22(27(34)39-4)25(18-20)41(5,37)38/h6-14,17-18,26H,15-16H2,1-5H3,(H,32,35)/t26-,31-/m0/s1

Standard InChI Key:  CSIIUZYJPVSIJG-HVNZXBJASA-N

Associated Targets(Human)

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha 132 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta 97 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

LXR-beta 3841 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

U-87 MG 3946 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 576.67Molecular Weight (Monoisotopic): 576.1930AlogP: 5.12#Rotatable Bonds: 4
Polar Surface Area: 119.08Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.15CX Basic pKa: CX LogP: 4.30CX LogD: 4.30
Aromatic Rings: 3Heavy Atoms: 41QED Weighted: 0.43Np Likeness Score: -0.24

References

1. Chen H,Chen Z,Zhang Z,Li Y,Zhang S,Jiang F,Wei J,Ding P,Zhou H,Gu Q,Xu J.  (2020)  Discovery of new LXRβ agonists as glioblastoma inhibitors.,  194  [PMID:32248003] [10.1016/j.ejmech.2020.112240]

Source